BR112018017228A2 - composições e métodos para regeneração do músculo usando prostaglandina e2 - Google Patents
composições e métodos para regeneração do músculo usando prostaglandina e2Info
- Publication number
- BR112018017228A2 BR112018017228A2 BR112018017228A BR112018017228A BR112018017228A2 BR 112018017228 A2 BR112018017228 A2 BR 112018017228A2 BR 112018017228 A BR112018017228 A BR 112018017228A BR 112018017228 A BR112018017228 A BR 112018017228A BR 112018017228 A2 BR112018017228 A2 BR 112018017228A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- pge2
- compound
- prostaglandin
- compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title 1
- 229960002986 dinoprostone Drugs 0.000 title 1
- 230000009756 muscle regeneration Effects 0.000 title 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title 1
- 210000000663 muscle cell Anatomy 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000003205 muscle Anatomy 0.000 abstract 2
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- -1 prostaglandin e2 (pge2) compound Chemical class 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
- C12N5/0659—Satellite cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0661—Smooth muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
Abstract
a presente invenção refere-se as composições, métodos e kits para a proliferação de células do músculo expondo as células do músculo a um composto ou composto de prostaglandina e2 (pge2) que ativa a sinalização de pge2. são também fornecidos os métodos para regenerar os músculos em um indivíduo que sofre de atrofia muscular, distrofia e/ou lesão por meio da administração de um composto de pge2 sozinho ou em combinação com células do músculo isoladas. o composto de pge2 em combinação com as células do músculo isoladas pode ser administrado de maneira profilática com a finalidade de prevenir uma doença ou condição muscular.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662303979P | 2016-03-04 | 2016-03-04 | |
US201662348116P | 2016-06-09 | 2016-06-09 | |
PCT/US2017/020650 WO2017152044A1 (en) | 2016-03-04 | 2017-03-03 | Compositions and methods for muscle regeneration using prostaglandin e2 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018017228A2 true BR112018017228A2 (pt) | 2019-02-05 |
Family
ID=59743257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018017228A BR112018017228A2 (pt) | 2016-03-04 | 2017-03-03 | composições e métodos para regeneração do músculo usando prostaglandina e2 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3423067A4 (pt) |
JP (2) | JP2019513010A (pt) |
KR (2) | KR102387896B1 (pt) |
CN (2) | CN109072186B (pt) |
AU (2) | AU2017225999B2 (pt) |
BR (1) | BR112018017228A2 (pt) |
CA (1) | CA3014667A1 (pt) |
WO (1) | WO2017152044A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9918994B2 (en) | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
WO2018102552A1 (en) | 2016-11-30 | 2018-06-07 | Case Western Reserve University | Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof |
WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
US11426420B2 (en) | 2017-04-07 | 2022-08-30 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
EP3634424A4 (en) | 2017-06-09 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS |
CN114206337A (zh) * | 2019-06-11 | 2022-03-18 | 莱兰斯坦福初级大学评议会 | 通过抑制15-羟基前列腺素脱氢酶(15-pgdh)使老化组织复壮的方法 |
WO2021052370A1 (en) * | 2019-09-16 | 2021-03-25 | Institute Of Zoology, Chinese Academy Of Sciences | Methods and compositions for tissue regeneration |
WO2022087631A1 (en) * | 2020-10-23 | 2022-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Elevation of mitochondrial biogenesis and function by inhibition of prostaglandin degrading enzyme 15-pgdh |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3927213A (en) * | 1973-07-10 | 1975-12-16 | American Home Prod | Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents |
US5143842A (en) | 1988-11-01 | 1992-09-01 | The University Of Colorado Foundation, Inc. | Media for normal human muscle satellite cells |
US5409911A (en) | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
US5833978A (en) * | 1995-03-16 | 1998-11-10 | Universite Laval | Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success |
US6841573B2 (en) * | 2002-11-27 | 2005-01-11 | Molecular Nutrition | Use of arachidonic acid as a method of increasing skeletal muscle mass |
US20070224167A1 (en) | 2006-02-09 | 2007-09-27 | Schering Corporation | Novel HCV inhibitor combinations and methods |
AU2007230902B2 (en) * | 2006-03-24 | 2013-03-14 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
EP2231162A1 (en) | 2007-11-29 | 2010-09-29 | Allergan, Inc. | Substituted cyclopentanes having prostaglandin activity |
US8871752B2 (en) * | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
CN102057037B (zh) | 2008-04-11 | 2014-06-18 | 学校法人庆应义塾 | 平滑肌干细胞的分离方法 |
US20130236433A1 (en) * | 2010-11-11 | 2013-09-12 | Keith A. Webster | Methods, compositions, cells, and kits for treating ischemic injury |
AU2013249434B2 (en) * | 2012-04-16 | 2017-10-12 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating 15-PGDH activity |
US20130331389A1 (en) * | 2012-06-11 | 2013-12-12 | National Cheng Kung University | Methods and Compositions for Cardiomyocyte Replenishment by Endogenous and Progenitor Stem Cells |
AU2014342811B2 (en) * | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
-
2017
- 2017-03-03 AU AU2017225999A patent/AU2017225999B2/en active Active
- 2017-03-03 KR KR1020187028393A patent/KR102387896B1/ko active IP Right Grant
- 2017-03-03 CA CA3014667A patent/CA3014667A1/en active Pending
- 2017-03-03 BR BR112018017228A patent/BR112018017228A2/pt active Search and Examination
- 2017-03-03 KR KR1020227012174A patent/KR102481354B1/ko active IP Right Grant
- 2017-03-03 WO PCT/US2017/020650 patent/WO2017152044A1/en active Application Filing
- 2017-03-03 CN CN201780014836.9A patent/CN109072186B/zh active Active
- 2017-03-03 CN CN202310631766.9A patent/CN116716241A/zh active Pending
- 2017-03-03 JP JP2018546415A patent/JP2019513010A/ja active Pending
- 2017-03-03 EP EP17760893.2A patent/EP3423067A4/en active Pending
-
2022
- 2022-06-01 JP JP2022089405A patent/JP2022116259A/ja active Pending
- 2022-11-10 AU AU2022268368A patent/AU2022268368A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20180129804A (ko) | 2018-12-05 |
CN116716241A (zh) | 2023-09-08 |
KR102387896B1 (ko) | 2022-04-15 |
EP3423067A4 (en) | 2019-09-04 |
JP2022116259A (ja) | 2022-08-09 |
JP2019513010A (ja) | 2019-05-23 |
KR102481354B1 (ko) | 2022-12-23 |
KR20220049615A (ko) | 2022-04-21 |
WO2017152044A1 (en) | 2017-09-08 |
AU2017225999A1 (en) | 2018-08-30 |
AU2022268368A1 (en) | 2022-12-15 |
EP3423067A1 (en) | 2019-01-09 |
CN109072186A (zh) | 2018-12-21 |
AU2017225999B2 (en) | 2022-08-18 |
CA3014667A1 (en) | 2017-09-08 |
CN109072186B (zh) | 2023-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018017228A2 (pt) | composições e métodos para regeneração do músculo usando prostaglandina e2 | |
AU2018253615A1 (en) | Adeno-associated virus mediated gene transfer to the central nervous system | |
CL2023002682A1 (es) | Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos | |
PH12015500435A1 (en) | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions | |
BR112017007662A2 (pt) | composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto | |
BR112018008358A2 (pt) | ?composições e métodos para terapia relacionada à microbiota fecal? | |
CL2019000266A1 (es) | Composición de cannabis. | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
UY32923A (es) | Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
BR112017018092A2 (pt) | composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio. | |
EA201591402A1 (ru) | Спиролактамные модуляторы nmda-рецептора и их применение | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
BR112015027563A2 (pt) | métodos para melhorar a regeneração do músculo envelhecido | |
WO2019067405A3 (en) | FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN | |
BR112017026287A2 (pt) | composições de hidroxipropil beta-ciclodextrina e métodos | |
BR112015017251A2 (pt) | composições farmacêuticas compreendendo doadores de nitroxil | |
BR112015018259A2 (pt) | Redução de resposta pró-inflamatória | |
BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
CL2011001943A1 (es) | Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso. | |
BR112016024176A2 (pt) | composições para tratamento bucal tendo estabilidade aprimorada | |
BR112018071602A2 (pt) | compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112012019921A2 (pt) | composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |